pI: 7.0354 |
Length (AA): 660 |
MW (Da): 78535 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 6 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
198 | 327 | 1p9o (A) | 33 | 167 | 32.00 | 0.000000000064 | 1 | 0.63 | -0.63 |
455 | 657 | 2gk4 (A) | 2 | 228 | 17.00 | 0 | 0.18 | 0.26 | -0.01 |
3 | 166 | 4u5a (C) | 50 | 239 | 22.00 | 0.03 | 0.11 | 0.371185 | -0.12 |
201 | 327 | 1p9o (A) | 36 | 167 | 32.00 | 0.0000035 | 0.99 | 0.506124 | 0.35 |
26 | 213 | 4u5a (A) | 48 | 240 | 22.00 | 0.028 | 0.02 | 0.378748 | -0.11 |
201 | 327 | 1p9o (A) | 36 | 167 | 32.00 | 0.000015 | 1 | 0.504324 | 0.39 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 32 hs, Female Gametocyte. | Otto TD Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, intra-erythrocytic - 24 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, gametocyte, sporozoite, early ring, early schizont, early trophozoite, late ring, late schizont, late trophozoite, Sporozoite. | Otto TD PlasmoDB Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Ring. | Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Oocyst, Male Gametocyte. | Zanghi G Lasonder E |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Ortholog group members (OG5_128432)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G12350 | phosphopantothenate--cysteine ligase 1 |
Arabidopsis thaliana | AT5G02080 | DNA / pantothenate metabolism flavoprotein |
Babesia bovis | BBOV_III006270 | DNA / pantothenate metabolism flavoprotein |
Brugia malayi | Bm1_45070 | DNA / pantothenate metabolism flavoprotein |
Candida albicans | CaO19.7357 | similar to S. cerevisiae YIL083C |
Cryptosporidium hominis | Chro.40256 | ENSANGP00000013327 |
Cryptosporidium parvum | cgd4_2250 | putative phosphopantothenoylcysteine synthetase |
Dictyostelium discoideum | DDB_G0282611 | phosphopantothenatecysteine ligase |
Drosophila melanogaster | Dmel_CG5629 | Phosphopantothenoylcysteine synthetase |
Echinococcus granulosus | EgrG_000906400 | yil083c protein |
Echinococcus multilocularis | EmuJ_000906400 | yil083c protein |
Homo sapiens | 79717 | phosphopantothenoylcysteine synthetase |
Leishmania braziliensis | LbrM.25.1460 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_251980.1 | phosphopantothenate--cysteine ligase, putative |
Leishmania infantum | LinJ.25.1980 | hypothetical protein, conserved |
Leishmania major | LmjF.25.1900 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.25.1900 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_01280 | DNA/pantothenate metabolism flavoprotein |
Mus musculus | ENSMUSG00000028636 | phosphopantothenoylcysteine synthetase |
Oryza sativa | 4344795 | Os08g0176100 |
Oryza sativa | 4329749 | Os02g0575200 |
Plasmodium berghei | PBANKA_0613600 | phosphopantothenate--cysteine ligase, putative |
Plasmodium falciparum | PF3D7_0412300 | phosphopantothenoylcysteine synthetase, putative |
Plasmodium falciparum | PF3D7_1102400 | phosphopantothenate--cysteine ligase, putative |
Plasmodium knowlesi | PKNH_0310500 | phosphopantothenate--cysteine ligase, putative |
Plasmodium vivax | PVX_000630 | phosphopantothenoylcysteine synthetase, putative |
Plasmodium yoelii | PY05326 | hypothetical protein |
Saccharomyces cerevisiae | YIL083C | phosphopantothenate--cysteine ligase CAB2 |
Schistosoma japonicum | Sjp_0215850 | ko:K01922 phosphopantothenate-cysteine ligase [EC6.3.2.5], putative |
Schistosoma japonicum | Sjp_0312350 | IPR007085,DNA/pantothenate metabolism flavoprotein, C-terminal,domain-containing |
Schistosoma japonicum | Sjp_0115150 | IPR007085,DNA/pantothenate metabolism flavoprotein, C-terminal,domain-containing |
Schistosoma mansoni | Smp_131090 | cornichon |
Schmidtea mediterranea | mk4.000616.08 | PhosphopantothenateALQ-cysteine ligase |
Trypanosoma brucei gambiense | Tbg972.3.1890 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.3.1970 | phosphopantothenoylcysteine synthetase, putative |
Trypanosoma congolense | TcIL3000_3_1070 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.504045.80 | hypothetical protein, conserved |
Toxoplasma gondii | TGME49_318600 | DNA /pantothenate metabolism flavoprotein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.3.1970 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.3.1970 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.3.1970 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.3.1970 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
YIL083C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_0613600 | Plasmodium berghei | Dispensable | plasmo |
TGME49_318600 | Toxoplasma gondii | Probably essential | sidik |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.1